HENGRUI PHARMA (01276) announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice for HRS-7535 tablets issued by the National Medical Products Administration, with clinical trials to be conducted in the near future. According to the Drug Administration Law of the People's Republic of China and relevant regulations, following a review, the HRS-7535 tablets, accepted on October 27, 2025, were deemed to meet the requirements for drug registration, approving the product to proceed with clinical trials. The applied indication is for the treatment of hypertension complicated by overweight or obesity. Reportedly, HRS-7535 tablets are a novel oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist. It is intended for treating type 2 diabetes (T2DM) and weight loss through mechanisms such as activating human GLP-1R to promote pancreatic insulin secretion, reduce glucagon secretion, inhibit gastric emptying, as well as influencing the central nervous system to enhance satiety, suppress appetite, and directly reduce energy intake. Globally, no oral small-molecule GLP-1R agonists are currently on the market. As of now, the cumulative R&D investment for projects related to HRS-7535 tablets amounts to approximately 369.4 million yuan.